Additionally, HA344, which is thought to be a potential application for overcoming cancer resistance, hinders the terminal and rate-limiting phases of glycolysis by covalently binding to PKM2 and blocking the activity of inosine monophosphate dehydrogenase (110). The gene discussed is PKM; the disease is cancer.